Packaging & Labelling
Packaging & Labelling
Catalent to sell US commercial packaging operations
Catalent Pharma Solutions has entered into a definitive agreement to sell its US commercial packaging operations based in Philadelphia, Pennsylvania, and Woodstock, Illinois, to a company affiliated with Frazier Healthcare. The transaction, which is...
Packaging & Labelling
AlpVision, Nolato partner to protect pharmaceutical primary plastic packaging
AlpVision and Nolato Medical have collaborated to protect primary plastic packaging and medical devices against counterfeiting. The AlpVision's patented Fingerprint technology is used in the partnership, which enables brand owners in the pharmaceutical industry...
Packaging & Labelling
FDA approves Sunovion Latuda label update to extend dose range
The FDA has approved the stretched dose range for Sunovion Pharmaceuticals' Latuda for the treatment of patients with schizophrenia. After the review of the supplemental new drug application (sNDA), which was submitted in June...
Packaging & Labelling
Almac Pharma Services expands packaging operations in US
Almac Pharma Services business unit has expanded its established commercial packaging operations with a $10m investment in a new 100,000sq ft commercial facility in Audubon, PA, US. The company clients will now be able...
Packaging & Labelling
Novartis to update high blood pressure drug label
Novartis has planned to update the Rasilez's labelling to include contraindications against combined use with a number of products. The company will follow the advice of the EMA's Committee for Medicinal Products for Human Use...
Packaging & Labelling
Pfizer recalls oral contraceptives due to packaging error
Pfizer has voluntarily recalled 14 lots of Lo/Ovral-28 and 14 lots of Norgestrel and Ethinyl Estradiol tablets in the US due to possibility of inexact tablet counts or out of sequence tablets. The products...
Packaging & Labelling
FDA approves TYSABRI label change
Biogen Idec and Elan have announced the FDA approval of a product label change for TYSABRI that will help enable individual benefit risk assessment for patients with multiple sclerosis (MS). The new label identifies anti-JCV...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read